financetom
Business
financetom
/
Business
/
Alibaba accelerates AI push by releasing new open-source models, text-to-video
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Alibaba accelerates AI push by releasing new open-source models, text-to-video
Sep 22, 2024 4:30 PM

BEIJING (Reuters) - Chinese technology company Alibaba ( BABA ) released on Thursday new open-source artificial intelligence models and text-to-video AI technology, intensifying its efforts to compete in the booming area of generative AI.

The open-source models, numbering more than 100, come from Alibaba's ( BABA ) Qwen 2.5 family, its latest foundational large language model released in May.

Chinese technology companies, like their U.S. counterparts, have been investing heavily in generative AI, with firms racing to develop robust product portfolios and diversified offerings.

While competitors such as Baidu ( BIDU ) and OpenAI have primarily adopted closed-source approaches, Alibaba ( BABA ) has embraced a hybrid model, investing in both proprietary and open-source development to broaden its AI product range.

Its new models range from 0.5 to 72 billion parameters - the variables that determine an AI model's capability and performance - in size, offering proficiency in mathematics, coding, and support for over 29 languages, Alibaba ( BABA ) said in a statement.

The models aim to cater to a wide array of AI applications across various sectors including automotive, gaming, and scientific research.

Alibaba ( BABA ) on Thursday also unveiled a new text-to-video model as part of its Tongyi Wanxiang image generation family, joining a growing number of Chinese tech firms entering this emerging market.

The move puts Alibaba ( BABA ) in direct competition with global players such as OpenAI, which has also shown interest in text-to-video technology.

In August, ByteDance, owner of TikTok, launched its text-to-video app Jimeng AI on Apple's App Store for Chinese users.

(Reporting by Liam Mo and Casey Hall; Editing by Muralikumar Anantharaman)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Soccer-Oaktree has no immediate plan to sell Inter Milan, source says
Soccer-Oaktree has no immediate plan to sell Inter Milan, source says
May 22, 2024
MILAN, May 22 (Reuters) - U.S. investment fund Oaktree Capital Management is not planning to sell Inter Milan immediately after it took control of the Italian soccer club following a missed debt payment, a source close to the matter said. Oaktree will be a patient investor, the source added. Earlier on Wednesday the U.S. investment firm said it had taken...
Molson Coors Beverage Company Up 0.6% In US Premarket As Proposes Public Offering of Euro-Denominated Senior Notes
Molson Coors Beverage Company Up 0.6% In US Premarket As Proposes Public Offering of Euro-Denominated Senior Notes
May 22, 2024
07:33 AM EDT, 05/22/2024 (MT Newswires) -- Molson Coors Beverage Company (TPX-A.TO, TPX-B.TO) on Wednesday commenced an underwritten public offering of euro-denominated senior notes. The Offering is expected to close on or about May 29, 2024, subject to customary closing conditions. Molson Coors said it intends to use the net proceeds of this Offering for general corporate purposes including the...
Biogen to buy Human Immunology Biosciences in up to $1.8 bln deal
Biogen to buy Human Immunology Biosciences in up to $1.8 bln deal
May 22, 2024
May 22 (Reuters) - Biogen said on Wednesday it had agreed to buy privately held Human Immunology Biosciences for $1.15 billion in upfront and up to $650 million in potential milestone payments. (Reporting by Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila) ...
Medicenna to Present Clinical Update on MDNA11 ABILITY-1 Trial at Sachs Oncology Innovation Forum
Medicenna to Present Clinical Update on MDNA11 ABILITY-1 Trial at Sachs Oncology Innovation Forum
May 22, 2024
07:34 AM EDT, 05/22/2024 (MT Newswires) -- Medicenna Therapeutics ( MDNAF ) , whose shares rose 4.4% yesterday, on Wednesday said it will present an update on the MDNA11 ABILITY-1 Trial at the 10th annual Sachs Oncology Innovation Forum on May 31. The company will present updated data from its Phase 1/2 ABILITY-1 study including anti-tumor activity, safety, pharmacokinetic and...
Copyright 2023-2026 - www.financetom.com All Rights Reserved